Does nilvadipine protect low-density lipoprotein cholesterol from in vivo oxidation in hypertensive patients with risk factors for atherosclerosis?
Our data showed that nilvadipine may protect LDL cholesterol from in vivo oxidation in hypertensive patients with high risk of atherosclerosis.
These findings reveal that rituximab-mediated inhibition of intracellular signaling pathways and leading to chemo/immuno-sensitization of resistant B-NHL is Fc independent.